(Q56336828)

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

More on: Discovery of alpha2-plasmin inhibitor and its congenital deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

The Low Density Lipoprotein Receptor-related Protein Modulates Protease Activity in the Brain by Mediating the Cellular Internalization of Both Neuroserpin and Neuroserpin-Tissue-type Plasminogen Activator Complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Tissue plasminogen activator: peptide analyses confirm an indirectly derived amino acid sequence, identify the active site serine residue, establish glycosylation sites, and localize variant differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Structural and kinetic comparison of recombinant human single- and two-chain tissue plasminogen activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Structure and function of human tissue-type plasminogen activator (t-PA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Established treatments for acute ischaemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Acute ischemic stroke: overview of recent therapeutic developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Experimental treatments for acute ischaemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Systemic reperfusion therapy in acute ischemic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Tissue plasminogen activator for acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

The ECASS 3-hour cohort. Secondary analysis of ECASS data by time stratification. ECASS Study Group. European Cooperative Acute Stroke Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Relationship between magnetic resonance arterial patency and perfusion-diffusion mismatch in acute ischemic stroke and its potential clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Noninvasive angiography (magnetic resonance and computed tomography) in the diagnosis of ischemic cerebrovascular disease. Techniques and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Thrombolytic therapy with streptokinase in acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

The plasminogen activator family from the salivary gland of the vampire bat Desmodus rotundus: cloning and expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Towards safer thrombolytic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Microplasmin reduces ischemic brain damage and improves neurological function in a rat stroke model monitored with MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Antithrombotic and hypofibrinogenetic therapy in acute ischemic stroke: what is the next step?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Emergent use of anticoagulation for treatment of patients with ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Argatroban tPA stroke study: study design and results in the first treated cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Neuroprotection and thrombolysis: combination therapy in acute ischaemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

NXY-059 for acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Advances in ischemic stroke treatment: neuroprotective and combination therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Tissue-type plasminogen activator is involved in the process of neuronal death induced by oxygen-glucose deprivation in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Tissue plasminogen activator protects hippocampal neurons from oxygen-glucose deprivation injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Modulation of zinc toxicity by tissue plasminogen activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Neuronal cell death and tPA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Recombinant tissue plasminogen activator reduces infarct size after reversible thread occlusion of middle cerebral artery in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Tissue plasminogen activator does not increase neuronal damage in rat models of global and focal ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Effects of recombinant tissue plasminogen activator after intraluminal thread occlusion in mice: role of hemodynamic alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Tissue plasminogen activator-induced ischemic injury is reversed by NMDA antagonist MK-801 in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Essential role of endogenous tissue plasminogen activator through matrix metalloproteinase 9 induction and expression on heparin-produced cerebral hemorrhage after cerebral ischemia in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Neutralizing the neurotoxic effects of exogenous and endogenous tPA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Magnetic resonance imaging indexes of therapeutic efficacy of recombinant tissue plasminogen activator treatment of rat at 1 and 4 hours after embolic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Tissue-type plasminogen activator has paradoxical roles in focal cerebral ischemic injury by thrombotic middle cerebral artery occlusion with mild or severe photochemical damage in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

LRP and alphavbeta3 mediate tPA activation of smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Reduced cortical injury and edema in tissue plasminogen activator knockout mice after brain trauma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

The long-term effect of recombinant tissue-plasminogen-activator (rt-PA) on edema formation in a large-animal model of intracerebral hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

The role of endogenous versus exogenous tPA on edema formation in murine ICH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix metalloproteinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Tissue plasminogen activator and NMDA receptor cleavage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Ethanol-withdrawal seizures are controlled by tissue plasminogen activator via modulation of NR2B-containing NMDA receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Neurotoxic responses by microglia elicited by excitotoxic injury in the mouse hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Proteolytic activation of monocyte chemoattractant protein-1 by plasmin underlies excitotoxic neurodegeneration in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Minor inflammation after surgical evacuation compared with fibrinolytic therapy of experimental intracerebral hemorrhages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Neuronal activity-dependent increase of net matrix metalloproteinase activity is associated with MMP-9 neurotoxicity after kainate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Reduction of excitotoxicity and associated leukocyte recruitment by a broad-spectrum matrix metalloproteinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Neuroserpin, a neuroprotective factor in focal ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824365

Acute [corrected] stroke thrombolysis: an update [corrected].

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824365

Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke. Results of the multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, part I

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824365

Matrix metalloproteinase activation and blood-brain barrier breakdown following thrombolysis

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824365

Intra-arterial reteplase compared to urokinase for thrombolytic recanalization in acute ischemic stroke.

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824365

Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824365

Tissue plasminogen activator mediates microglial activation via its finger domain through annexin II.

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824365

Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trial

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824365

Intra-arterial third-generation recombinant tissue plasminogen activator (reteplase) for acute ischemic stroke

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824365

Polyethylene glycol-derivatized cysteine-substitution variants of recombinant staphylokinase for single-bolus treatment of acute myocardial infarction.

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824365

Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824365

Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824365

Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824365

Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824365

Expression of neuroserpin, an inhibitor of tissue plasminogen activator, in the developing and adult nervous system of the mouse.

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824365

Neuroserpin, an axonally secreted serine protease inhibitor

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824365

The search for the ideal thrombolytic agent: maximize the benefit and minimize the risk

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824365

Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial--Italy (MAST-I) Group

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824365

Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824365

Studies on the kinetics of plasminogen activation by tissue plasminogen activator

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824365

Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans.

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824365

Isolation, characterization, and cDNA cloning of a vampire bat salivary plasminogen activator

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824365

Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824365

Vampire bat salivary plasminogen activator exhibits a strict and fastidious requirement for polymeric fibrin as its cofactor, unlike human tissue-type plasminogen activator. A kinetic analysis

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824365

Ultrasound-Enhanced Systemic Thrombolysis for Acute Ischemic Stroke

7 September 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Physiological consequences of loss of plasminogen activator gene function in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.2.159

Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits

21 January 2018

1 reference

12 December 2020

tPA and proteolysis in the neurovascular unit

1 reference

12 December 2020

Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture

1 reference

12 December 2020

CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group

1 reference

12 December 2020

An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus

1 reference

12 December 2020

1 reference

12 December 2020

The Desmoteplase in Acute Ischemic Stroke Trial (DIAS)

1 reference

12 December 2020

1 reference

12 December 2020

Discovery of alpha2-plasmin inhibitor and its congenital deficiency

1 reference

12 December 2020

Reassessment of defibrase in treatment of acute cerebral infarction: a multicenter, randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset

1 reference

12 December 2020

Reduction of tissue plasminogen activator-induced matrix metalloproteinase-9 by simvastatin in astrocytes

1 reference

12 December 2020

Activation of microglia reveals a non-proteolytic cytokine function for tissue plasminogen activator in the central nervous system

1 reference

12 December 2020

Tissue type plasminogen activator amplifies hemoglobin-induced neurotoxicity in rat neuronal cultures

1 reference

12 December 2020

Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial

1 reference

12 December 2020

Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke

1 reference

12 December 2020

Effects of tissue type plasminogen activator in embolic versus mechanical models of focal cerebral ischemia in rats

1 reference

12 December 2020

Microglial tissue plasminogen activator (tPA) triggers neuronal apoptosis in vitro

1 reference

12 December 2020

Abciximab in acute ischemic stroke. A randomized, double-blind, placebo-controlled, dose-escalation study

1 reference

12 December 2020

Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis

1 reference

12 December 2020

Common evolutionary origin of the fibrin-binding structures of fibronectin and tissue-type plasminogen activator

1 reference

12 December 2020

Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells

1 reference

12 December 2020

Isolation and functional characterization of the heavy and light chains of human tissue-type plasminogen activator

1 reference

12 December 2020

Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction

1 reference

12 December 2020

The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group

1 reference

12 December 2020

Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II)

1 reference

12 December 2020

10.1517/14728222.12.2.159

Identifiers

DOI

0 references

Fatcat ID

release_dhcp6wugfzfa3djwific4svhne

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/dhcp6wugfzfa3djwific4svhne

24 November 2022